126 related articles for article (PubMed ID: 37885165)
1. Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end. Authors' reply.
Gao N; Guan G; Zhao Q; Gao Z
Aliment Pharmacol Ther; 2023 Nov; 58(10):1105-1106. PubMed ID: 37885165
[No Abstract] [Full Text] [Related]
2. Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end.
Mak LY
Aliment Pharmacol Ther; 2023 Nov; 58(10):1103-1104. PubMed ID: 37885169
[No Abstract] [Full Text] [Related]
3. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. LAG3
Pang XQ; Li X; Zhu WH; Huang RK; Mo ZS; Huang ZX; Zhang Y; Xie DY; Gao ZL
Antiviral Res; 2023 May; 213():105592. PubMed ID: 37004734
[TBL] [Abstract][Full Text] [Related]
6. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
8. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
9. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
10. Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
Bichoupan K; Schwartz JM; Martel-Laferriere V; Giannattasio ER; Marfo K; Odin JA; Liu LU; Schiano TD; Perumalswami P; Bansal M; Gaglio PJ; Kalia H; Dieterich DT; Branch AD; Reinus JF
Aliment Pharmacol Ther; 2014 Mar; 39(5):543. PubMed ID: 24494843
[No Abstract] [Full Text] [Related]
11. Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha.
Liu Y; Zheng Y; Lin X; Cao Z; Lu J; Ma L; Ren S; Zheng S; Hu Z; Xu B; Chen X
BMC Endocr Disord; 2023 May; 23(1):115. PubMed ID: 37217910
[TBL] [Abstract][Full Text] [Related]
12. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
13. The treatment of hepatitis B e antigen-positive chronic hepatitis B with pegylated interferon.
Cooksley G
J Hepatol; 2003; 39 Suppl 1():S143-5. PubMed ID: 14708693
[No Abstract] [Full Text] [Related]
14. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.
Zhang XQ; Zhang HY; You JP; Mao Q
Virol J; 2013 Jan; 10():21. PubMed ID: 23320822
[TBL] [Abstract][Full Text] [Related]
16. [Pegylated interferon treatment and severe thrombocytopenia].
Rodríguez-García G; Jiménez-Macías F; Fernández-Jurado A; Domínguez-Macías A
Med Clin (Barc); 2006 Sep; 127(8):316-7. PubMed ID: 16949021
[No Abstract] [Full Text] [Related]
17. Superficial venous thrombophlebitis associated with pegylated interferon alpha-2a treatment in a patient with chronic hepatitis B.
Kalafateli M; Triantos C; Kakkos SK; Mougiou A; Labropoulou-Karatza C
J Gastrointestin Liver Dis; 2012 Sep; 21(3):328-9. PubMed ID: 23012682
[No Abstract] [Full Text] [Related]
18. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
[TBL] [Abstract][Full Text] [Related]
19. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
Thomas WL; Ramos F; Hospenthal DR
Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
[TBL] [Abstract][Full Text] [Related]
20. Acute pancreatitis during pegylated interferon therapy in a patient with chronic hepatitis B.
Vignon RK; Seddik H; Rouibaa F; En-Nouali H; Kabbaj N; Benkirane A
J Gastrointestin Liver Dis; 2009 Dec; 18(4):512. PubMed ID: 20076835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
